^
Association details:
Biomarker:No biomarker
Cancer:Renal Cell Carcinoma
Drug:everolimus (mTOR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
AFINITOR is a kinase inhibitor indicated for the treatment of:...Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
Evidence Level:
Sensitive: A1 - Approval
New
Excerpt:
Afinitor is indicated for the treatment of patients with advanced renal-cell carcinoma...
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
...the NCCN Panel has included everolimus as a category 2A, other recommended option for patients with non-clear cell RCC.
Evidence Level:
Sensitive: B - Late Trials
Title:

Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial

Published date:
10/18/2020
Excerpt:
Patients with clear cell mRCC failing one initial VEGFR‐TKI received everolimus...Median PFS and median OS were 3.8 months (95%‐CI 3.2‐6.2) and 16.8 months (95%‐CI 14.3‐24.3). ORR was 7.9%, disease control rate 60.3%....Everolimus remains a safe and effective treatment option for mRCC patients...
DOI:
10.1002/ijc.33349